A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia.

Trial Profile

A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Dasatinib (Primary) ; Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 Planned primary completion date changed from 1 Jan 2010 to 1 Dec 2009.
    • 14 Jul 2017 Status changed from recruiting to withdrawn prior to enrolment as Unable to enroll.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top